Egetis Therapeutics AB (publ) (EGTX) - Net Assets
Based on the latest financial reports, Egetis Therapeutics AB (publ) (EGTX) has net assets worth Skr248.70 Million SEK (≈ $26.76 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr537.40 Million ≈ $57.83 Million USD) and total liabilities (Skr288.70 Million ≈ $31.07 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check EGTX PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr248.70 Million |
| % of Total Assets | 46.28% |
| Annual Growth Rate | 28.07% |
| 5-Year Change | -35.74% |
| 10-Year Change | -13.06% |
| Growth Volatility | 311.38 |
Egetis Therapeutics AB (publ) - Net Assets Trend (2008–2025)
This chart illustrates how Egetis Therapeutics AB (publ)'s net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see EGTX market cap overview.
Annual Net Assets for Egetis Therapeutics AB (publ) (2008–2025)
The table below shows the annual net assets of Egetis Therapeutics AB (publ) from 2008 to 2025. Also explore net asset momentum of Egetis Therapeutics AB (publ) to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | Skr338.70 Million ≈ $36.45 Million |
-31.28% |
| 2024-12-31 | Skr492.90 Million ≈ $53.04 Million |
-9.66% |
| 2023-12-31 | Skr545.60 Million ≈ $58.72 Million |
+7.78% |
| 2022-12-31 | Skr506.20 Million ≈ $54.48 Million |
-3.95% |
| 2021-12-31 | Skr527.04 Million ≈ $56.72 Million |
-16.29% |
| 2020-12-31 | Skr629.63 Million ≈ $67.76 Million |
+157.12% |
| 2019-12-31 | Skr244.88 Million ≈ $26.35 Million |
+11.63% |
| 2018-12-31 | Skr219.36 Million ≈ $23.61 Million |
-27.77% |
| 2017-12-31 | Skr303.71 Million ≈ $32.68 Million |
-22.04% |
| 2016-12-31 | Skr389.56 Million ≈ $41.92 Million |
+711.05% |
| 2015-12-31 | Skr48.03 Million ≈ $5.17 Million |
-47.02% |
| 2014-12-31 | Skr90.66 Million ≈ $9.76 Million |
+93.08% |
| 2013-12-31 | Skr46.95 Million ≈ $5.05 Million |
-12.95% |
| 2012-12-31 | Skr53.94 Million ≈ $5.80 Million |
-38.38% |
| 2011-12-31 | Skr87.53 Million ≈ $9.42 Million |
+1152.27% |
| 2010-12-31 | Skr6.99 Million ≈ $752.22K |
+23.92% |
| 2009-12-31 | Skr5.64 Million ≈ $607.01K |
+11.75% |
| 2008-12-31 | Skr5.05 Million ≈ $543.18K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Egetis Therapeutics AB (publ)'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 194745061600.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr22.30 Million | 6.58% |
| Other Comprehensive Income | Skr36.90 Million | 10.89% |
| Other Components | Skr2.23 Billion | 657.75% |
| Total Equity | Skr338.70 Million | 100.00% |
Egetis Therapeutics AB (publ) Competitors by Market Cap
The table below lists competitors of Egetis Therapeutics AB (publ) ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Parpro Corp
TW:4916
|
$400.41 Million |
|
Wei Long Grape Wine Co Ltd
SHG:603779
|
$400.42 Million |
|
Tus-Sound Environmental Resources Co Ltd
SHE:000826
|
$400.46 Million |
|
Simei Media Co Ltd
SHE:002712
|
$400.61 Million |
|
Sejin Heavy Industries Co Ltd
KO:075580
|
$400.29 Million |
|
Hubei Yingtong Telecommunication Cable Co Ltd
SHE:002861
|
$400.17 Million |
|
Canopy Growth Corp
TO:WEED
|
$400.05 Million |
|
Henan Qingshuiyuan Technology Co Ltd
SHE:300437
|
$400.03 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Egetis Therapeutics AB (publ)'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 492,800,000 to 338,700,000, a change of -154,100,000 (-31.3%).
- Net loss of 342,500,000 reduced equity.
- New share issuances of 183,200,000 increased equity.
- Other comprehensive income increased equity by 12,000,000.
- Other factors decreased equity by 6,800,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-342.50 Million | -101.12% |
| Share Issuances | Skr183.20 Million | +54.09% |
| Other Comprehensive Income | Skr12.00 Million | +3.54% |
| Other Changes | Skr-6.80 Million | -2.01% |
| Total Change | Skr- | -31.27% |
Book Value vs Market Value Analysis
This analysis compares Egetis Therapeutics AB (publ)'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 8.70x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.51x to 8.70x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2008-12-31 | Skr15.71 | Skr8.00 | x |
| 2009-12-31 | Skr17.56 | Skr8.00 | x |
| 2010-12-31 | Skr18.99 | Skr8.00 | x |
| 2011-12-31 | Skr3.95 | Skr8.00 | x |
| 2012-12-31 | Skr1.97 | Skr8.00 | x |
| 2013-12-31 | Skr1.69 | Skr8.00 | x |
| 2014-12-31 | Skr3.01 | Skr8.00 | x |
| 2015-12-31 | Skr1.53 | Skr8.00 | x |
| 2016-12-31 | Skr11.85 | Skr8.00 | x |
| 2017-12-31 | Skr5.64 | Skr8.00 | x |
| 2018-12-31 | Skr4.08 | Skr8.00 | x |
| 2019-12-31 | Skr4.29 | Skr8.00 | x |
| 2020-12-31 | Skr8.57 | Skr8.00 | x |
| 2021-12-31 | Skr2.93 | Skr8.00 | x |
| 2022-12-31 | Skr2.61 | Skr8.00 | x |
| 2023-12-31 | Skr2.10 | Skr8.00 | x |
| 2024-12-31 | Skr1.61 | Skr8.00 | x |
| 2025-12-31 | Skr0.92 | Skr8.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Egetis Therapeutics AB (publ) utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -101.12%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -548.88%
- • Asset Turnover: 0.10x
- • Equity Multiplier: 1.89x
- Recent ROE (-101.12%) is below the historical average (-44.90%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2008 | -11.08% | 0.00% | 0.00x | 1.06x | Skr-1.06 Million |
| 2009 | -23.86% | 0.00% | 0.00x | 1.05x | Skr-1.91 Million |
| 2010 | -54.37% | -142559.04% | 0.00x | 1.21x | Skr-4.50 Million |
| 2011 | -37.98% | 0.00% | 0.00x | 1.04x | Skr-42.00 Million |
| 2012 | -62.77% | 0.00% | 0.00x | 1.12x | Skr-39.25 Million |
| 2013 | -54.41% | 0.00% | 0.00x | 1.09x | Skr-30.24 Million |
| 2014 | -53.41% | 0.00% | 0.00x | 1.14x | Skr-57.49 Million |
| 2015 | -91.26% | 0.00% | 0.00x | 1.09x | Skr-48.64 Million |
| 2016 | -9.81% | 0.00% | 0.00x | 1.02x | Skr-77.18 Million |
| 2017 | -28.95% | -647.29% | 0.04x | 1.04x | Skr-118.31 Million |
| 2018 | -38.75% | -301.31% | 0.12x | 1.10x | Skr-106.94 Million |
| 2019 | -25.09% | -74.40% | 0.31x | 1.10x | Skr-85.92 Million |
| 2020 | -28.45% | -440.51% | 0.05x | 1.42x | Skr-242.08 Million |
| 2021 | -19.87% | -273.85% | 0.07x | 1.08x | Skr-157.43 Million |
| 2022 | -37.44% | -842.22% | 0.04x | 1.11x | Skr-240.12 Million |
| 2023 | -59.92% | -567.53% | 0.08x | 1.39x | Skr-381.46 Million |
| 2024 | -69.72% | -745.34% | 0.06x | 1.61x | Skr-392.88 Million |
| 2025 | -101.12% | -548.88% | 0.10x | 1.89x | Skr-376.37 Million |
Industry Comparison
This section compares Egetis Therapeutics AB (publ)'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $48,330,800
- Average return on equity (ROE) among peers: -134.76%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Egetis Therapeutics AB (publ) (EGTX) | Skr248.70 Million | -11.08% | 1.16x | $400.29 Million |
| 2cureX AB (2CUREX) | $13.62 Million | -53.33% | 0.76x | $1.13 Million |
| Ascelia Pharma AB (publ) (ACE) | $111.73 Million | -21.83% | 0.04x | $7.82 Million |
| AcouSort AB (ACOU) | $8.46 Million | -178.16% | 0.46x | $6.29 Million |
| Active Biotech AB (ACTI) | $22.11 Million | -145.24% | 0.45x | $11.91 Million |
| Alzinova AB (ALZ) | $121.96 Million | -21.54% | 0.18x | $9.10 Million |
| AlzeCure Pharma (ALZCUR) | $32.97 Million | -235.89% | 0.38x | $95.97 Million |
| Annexin Pharmaceuticals AB (ANNX) | $13.71 Million | -366.46% | 0.39x | $9.68 Million |
| Alligator Bioscience AB (ATORX) | $68.52 Million | -112.06% | 0.43x | $2.35 Million |
| BioInvent International AB (BINV) | $29.45 Million | -307.87% | 0.85x | $158.63 Million |
| BioArctic AB (publ) (BIOA-B) | $60.76 Million | 94.77% | 10.65x | $2.60 Billion |
About Egetis Therapeutics AB (publ)
Egetis Therapeutics AB (publ), a pharmaceutical company, engages in the development and commercialization of orphan drugs in Sweden and internationally. It develops Aladote, which is in Phase IIb/III clinical trial for the treatment of paracetamol/acetaminophen overdosing and for the prevention of acute liver failure in paracetamol poisoning; and Emcitate, which is in Phase IIb clinical trial for… Read more